newsfilter
← Latest News
GlobeNewswire·

Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)

- NL-201 plus pembrolizumab to be evaluated in advanced solid tumor patients -- Combination testing anticipated to begin in 2022 - SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceuti